BACKGROUND: Niemann-Pick disease type C (NPC) is an ultra-rare, progressive, genetic disease leading to impaired lysosomal function and neurodegeneration causing serious morbidity and shortened life expectancy. The Niemann-Pick type C Clinical Severity Scale (NPCCSS) is a 17 domain, disease-specific, clinician-reported outcome measure of disease severity and progression. An abbreviated 5-domain NPCCSS scale has been developed (measuring Ambulation, Swallow, Cognition, Speech, and Fine Motor Skills) and the scale reliability has been established. Additional psychometric properties and meaningful change of the scale need, however, to be assessed. METHODS: Mixed method studies were conducted to ascertain which NPCCSS domains were most important, as well as to explore meaningful change: 1) surveys in caregivers/patients (n = 49) and 2) interviews with clinicians (n = 5) as well as caregivers/patients (n = 28). Clinical trial data (n = 43) assessed construct validity and meaningful change through an anchor-based approach. RESULTS: Domains identified as most important by clinicians, caregivers, and patients (independent of current age, age of onset, and disease severity) were Ambulation, Swallow, Cognition, Speech, and Fine Motor Skills, indicating content validity of the 5-domain NPCCSS. Criterion validity was shown with the 5-domain NPCCSS being highly correlated with the 17-item NPCCSS total score (excluding hearing domains), r2 = 0.97. Convergent validity was demonstrated against the 9 Hole Peg Test, r2 = 0.65 (n = 31 patients), and the Scale for Assessment and Rating of Ataxia (SARA), r2 = 0.86 (n = 49 patients). Any change was seen as meaningful by patients/caregivers across domains. Meaningful change using trial data and interviews with NPC experts (n = 5) and patients/caregivers (n = 28) suggested that a 1-category change on a domain is equivalent to 1-point change or greater in the 5-domain NPCCSS total score. CONCLUSIONS: Qualitative and quantitative data support content and construct validity of the 5-domain NPCCSS score as a valid endpoint in NPC trials. A 1-category change on any domain is equivalent to 1-point change or greater in the 5 domain NPCCSS total score, representing a clinically meaningful transition and reflecting loss of complex function and increased disability. Trial registration NCT02612129. Registered 23 November 2015, https://clinicaltrials.gov/ct2/show/NCT02612129.
BACKGROUND:Niemann-Pick disease type C (NPC) is an ultra-rare, progressive, genetic disease leading to impaired lysosomal function and neurodegeneration causing serious morbidity and shortened life expectancy. The Niemann-Pick type C Clinical Severity Scale (NPCCSS) is a 17 domain, disease-specific, clinician-reported outcome measure of disease severity and progression. An abbreviated 5-domain NPCCSS scale has been developed (measuring Ambulation, Swallow, Cognition, Speech, and Fine Motor Skills) and the scale reliability has been established. Additional psychometric properties and meaningful change of the scale need, however, to be assessed. METHODS: Mixed method studies were conducted to ascertain which NPCCSS domains were most important, as well as to explore meaningful change: 1) surveys in caregivers/patients (n = 49) and 2) interviews with clinicians (n = 5) as well as caregivers/patients (n = 28). Clinical trial data (n = 43) assessed construct validity and meaningful change through an anchor-based approach. RESULTS: Domains identified as most important by clinicians, caregivers, and patients (independent of current age, age of onset, and disease severity) were Ambulation, Swallow, Cognition, Speech, and Fine Motor Skills, indicating content validity of the 5-domain NPCCSS. Criterion validity was shown with the 5-domain NPCCSS being highly correlated with the 17-item NPCCSS total score (excluding hearing domains), r2 = 0.97. Convergent validity was demonstrated against the 9 Hole Peg Test, r2 = 0.65 (n = 31 patients), and the Scale for Assessment and Rating of Ataxia (SARA), r2 = 0.86 (n = 49 patients). Any change was seen as meaningful by patients/caregivers across domains. Meaningful change using trial data and interviews with NPC experts (n = 5) and patients/caregivers (n = 28) suggested that a 1-category change on a domain is equivalent to 1-point change or greater in the 5-domain NPCCSS total score. CONCLUSIONS: Qualitative and quantitative data support content and construct validity of the 5-domain NPCCSS score as a valid endpoint in NPC trials. A 1-category change on any domain is equivalent to 1-point change or greater in the 5 domain NPCCSS total score, representing a clinically meaningful transition and reflecting loss of complex function and increased disability. Trial registration NCT02612129. Registered 23 November 2015, https://clinicaltrials.gov/ct2/show/NCT02612129.
Entities:
Keywords:
Arimoclomol; ClinRO; NPCCSS; Niemann-pick type C clinical severity scale; Validation
Authors: Nicole M Yanjanin; Jorge I Vélez; Andrea Gropman; Kelly King; Simona E Bianconi; Sandra K Conley; Carmen C Brewer; Beth Solomon; William J Pavan; Mauricio Arcos-Burgos; Marc C Patterson; Forbes D Porter Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2010-01-05 Impact factor: 3.568
Authors: T Schmitz-Hübsch; S Tezenas du Montcel; L Baliko; J Berciano; S Boesch; C Depondt; P Giunti; C Globas; J Infante; J-S Kang; B Kremer; C Mariotti; B Melegh; M Pandolfo; M Rakowicz; P Ribai; R Rola; L Schöls; S Szymanski; B P van de Warrenburg; A Dürr; T Klockgether; Roberto Fancellu Journal: Neurology Date: 2006-06-13 Impact factor: 9.910
Authors: S Naureckiene; D E Sleat; H Lackland; A Fensom; M T Vanier; R Wattiaux; M Jadot; P Lobel Journal: Science Date: 2000-12-22 Impact factor: 47.728
Authors: Daniel S Ory; Elizabeth A Ottinger; Nicole Yanjanin Farhat; Kelly A King; Xuntian Jiang; Lisa Weissfeld; Elizabeth Berry-Kravis; Cristin D Davidson; Simona Bianconi; Lee Ann Keener; Ravichandran Rao; Ariane Soldatos; Rohini Sidhu; Kimberly A Walters; Xin Xu; Audrey Thurm; Beth Solomon; William J Pavan; Bernardus N Machielse; Mark Kao; Steven A Silber; John C McKew; Carmen C Brewer; Charles H Vite; Steven U Walkley; Christopher P Austin; Forbes D Porter Journal: Lancet Date: 2017-08-10 Impact factor: 202.731
Authors: Tarekegn Geberhiwot; Alessandro Moro; Andrea Dardis; Uma Ramaswami; Sandra Sirrs; Mercedes Pineda Marfa; Marie T Vanier; Mark Walterfang; Shaun Bolton; Charlotte Dawson; Bénédicte Héron; Miriam Stampfer; Jackie Imrie; Christian Hendriksz; Paul Gissen; Ellen Crushell; Maria J Coll; Yann Nadjar; Hans Klünemann; Eugen Mengel; Martin Hrebicek; Simon A Jones; Daniel Ory; Bruno Bembi; Marc Patterson Journal: Orphanet J Rare Dis Date: 2018-04-06 Impact factor: 4.123
Authors: Mario Cortina-Borja; Danielle Te Vruchte; Eugen Mengel; Yasmin Amraoui; Jackie Imrie; Simon A Jones; Christine I Dali; Paul Fineran; Thomas Kirkegaard; Heiko Runz; Robin Lachmann; Tatiana Bremova-Ertl; Michael Strupp; Frances M Platt Journal: Orphanet J Rare Dis Date: 2018-08-16 Impact factor: 4.123
Authors: Eugen Mengel; Bruno Bembi; Mireia Del Toro; Federica Deodato; Matthias Gautschi; Stephanie Grunewald; Sabine Grønborg; Bénédicte Héron; Esther M Maier; Agathe Roubertie; Saikat Santra; Anna Tylki-Szymanska; Simon Day; Tara Symonds; Stacie Hudgens; Marc C Patterson; Christina Guldberg; Linda Ingemann; Nikolaj H T Petersen; Thomas Kirkegaard; Christine Í Dali Journal: Orphanet J Rare Dis Date: 2020-11-23 Impact factor: 4.123
Authors: Eugen Mengel; Marc C Patterson; Rosalia M Da Riol; Mireia Del Toro; Federica Deodato; Matthias Gautschi; Stephanie Grunewald; Sabine Grønborg; Paul Harmatz; Bénédicte Héron; Esther M Maier; Agathe Roubertie; Saikat Santra; Anna Tylki-Szymanska; Simon Day; Anne Katrine Andreasen; Marie Aavang Geist; Nikolaj Havnsøe Torp Petersen; Linda Ingemann; Thomas Hansen; Thomas Blaettler; Thomas Kirkegaard; Christine Í Dali Journal: J Inherit Metab Dis Date: 2021-09-07 Impact factor: 4.750
Authors: Eugen Mengel; Marc C Patterson; Michael Chladek; Christina Guldberg; Christine Í Dali; Tara Symonds; Lucy Lloyd-Price; Toni Mathieson; Joslyn Crowe; Claire Burbridge Journal: Orphanet J Rare Dis Date: 2021-11-24 Impact factor: 4.123
Authors: Beth I Solomon; Andrea M Muñoz; Ninet Sinaii; Nicole M Farhat; Andrew C Smith; Simona Bianconi; An Dang Do; Michael C Backman; Leonza Machielse; Forbes D Porter Journal: Orphanet J Rare Dis Date: 2022-09-05 Impact factor: 4.303